To Assess Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine or Allisartan Isoproxil
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 499 participants.
Also called NCT06465264
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 499 participants
- Registry
-
NCT06465264
-
- Other papers using this trial's data
- Efficacy and Safety of Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled by Amlodipine: A Phase III, Multicenter, Double-Blind, Parallel-Group, Randomized Controlled Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06465264. Randomized; quadruple masking; primary purpose treatment. Start 2021-04-29 (actual); primary completion 2022-08-16 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- To Assess Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine or Allisartan Isoproxil
- Condition
- Essential Hypertension
- Intervention (Drug)
- Allisartan Isoproxil/Amlodipine group 1
- Intervention (Drug)
- Amlodipine group 1
- Intervention (Drug)
- Allisartan Isoproxil/Amlodipine group 2
- Intervention (Drug)
- Allisartan Isoproxil group 2
- Lead sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Record details
- Record id
cardio:ct-nct06465264- Content hash
d8236e801945109b2c5ac1da9c30f9786d75a5a853c7d8181adf579140273517